西黄丸联合GP方案治疗晚期乳腺癌的疗效观察

Therapeutic effects of Xihuang Pills combined with GP chemotherapy on advanced breast cancer

目的观察西黄丸联合GP方案治疗晚期乳腺癌的临床疗效。方法选取2017年1月至2019年4月收治的晚期乳腺癌患者110例,随机分为对照组和观察组,每组55例。2组均给予GP方案治疗,观察组在GP方案基础上加用西黄丸治疗。观察2组近期疗效、远期疗效、1年复发率和生存率及不良反应发生情况,比较2组治疗前后血清肿瘤标志物、雌激素及血常规变化。结果对照组缓解率和疾病控制率分别为56.36%、78.18%,观察组缓解率和疾病控制率分别为78.18%、92.73%;观察组近期疗效优于对照组(P<0.05)。对照组PFS和OS分别为(6.37±0.84)个月、(12.00±1.72)个月,观察组PFS和OS分别为(10.42±1.26)个月、(15.33±2.18)个月;观察组远期疗效优于对照组(P<0.05)。随访1年,对照组复发率和生存率分别为16.36%、58.18%,观察组复发率和生存率分别为5.45%、81.82%。观察组复发率低于对照组,生存率高于对照组(P<0.05)。2组不良反应发生情况差异无统计学意义(P>0.05)。2组治疗前血清CEA、CA125、CA153、E1、E2及Hb、WBC、PLT比较差异无统计学意义(P>0.05),2组治疗后血清CEA、CA125、CA153、E1、E2及Hb、WBC、PLT均较治疗前降低(P<0.05),且观察组CEA、CA125、CA153、E1、E2低于对照组,Hb、WBC、PLT高于对照组(P<0.05)。结论西黄丸联合GP方案治疗晚期乳腺癌具有良好的临床疗效,能够显著提高近期疗效和远期疗效,降低血清肿瘤标志物和雌激素水平,减轻骨髓抑制,且安全性高。

Objective To investigate the therapeutic effects of Xihuang Pills combined with GP chemotherapy on advanced breast cancer.Methods A total of 110 patients with advanced breast cancer were who were treated in our hospital from January 2017 to April 2019 were enrolled in the artusy,who were randomly divided into observation group and control group,with 55 cases in each group.The patients in both groups were treated by GP chemotherapy,on that basi,the patients in observation group were treated by oral Xihuang pills.After treatment,the short-term and long-term curative effects,1-year recurrence rate,survival rate and incidence rate of adverse effects were observed and compared between the two groups.Moreover the changes of serum tumor markers,estrogen and blood routine before and after treatment were observed and compared between the two groups.Results The remission rate and disease control rate in control group were 56.36%and 78.18%,respectively,which were 78.18%and 92.73%in observation group,respectively,and the short-term curative effects in observation group were superior to those in control group(P<0.05).The PFS and OS in control group were(6.37±0.84)months and(12.00±1.72)months,respectively,which were(10.42±1.26)month and(15.33±2.18)month in observation group,respectively,and the long-term curative effects in observation group were superior to those in control group(P<0.05).Moreover the recurrence rate and survival rate were 16.36%and 58.18%in control group,respectively,which were 5.45%and 81.82%in observation group,respectively,and the long-term curative effects in observation group were superior to those in control group(P<0.05).There were no significant differences in the incidence rates of myelosuppression,gastrointestinal reaction,alopecia,renal dysfunction and liver dysfunction between the two groups(P>0.05).Before treatment,there were no significant differences in serum levels of CEA,CA125,CA153,E1,E2 and Hb,WBC,PLT between the two groups(P>0.05).After treatment,the serum levels of CEA,CA125,CA153,E1,E2,and Hb,WBC,PLT were significantly decreased in both groups(P<0.05),moreover,the serum levels of CEA,CA125,CA153,E1,E2 in observation group were significantly lower than those in control group,however,the levels of Hb,WBC,PLT in observation group were significantly higher than those in control group(P<0.05).Conclusion Xihuang Pills combined with GP chemotherapy has good clinical curative effects on advanced breast cancer,which can effectively improve the short-term and long-term curative effects,r`educe the serum levels of tumor markers and estrogen,and relieve the myelosuppression,with better safety.